The Personalized Medicine Coalition, representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system.
PARADIGM SHIFTS, ESPECIALLY IN MEDICINE, DO NOT HAPPEN JUST BECAUSE THE SCIENCE AND NEW TECHNOLOGIES SUGGEST THEY SHOULD.

Based on this assumption, some 20 institutions launched the Personalized Medicine Coalition in 2004 to develop a new medical paradigm that links treatment decisions to diagnostics.

Believing in an ecosystem of shared value across the multiple stakeholders it represents, the Coalition advocates for changes that will increase investment in personalized medicine and facilitate its clinical adoption so that both patients and health systems will benefit from improved health care and increased efficiency.

WHAT IS PERSONALIZED MEDICINE?

Personalized medicine is an evolving field in which physicians use diagnostic tests to determine which medical treatments will work best for each patient or use medical interventions to alter molecular mechanisms that impact health. By combining data from diagnostic tests with an individual’s medical history, circumstances and values, health care providers can develop targeted treatment and prevention plans with their patients.
PMC WORKS TO ENSURE THAT POLICIES AND PRACTICES IN THE PUBLIC AND PRIVATE SECTORS PAVE THE WAY FOR PERSONALIZED MEDICINE.

Based in Washington, D.C., PMC works closely with health systems, lawmakers and agency officials to advance strategic priorities in three areas:

- **Education:** To raise the profile and scope of personalized medicine, PMC proactively educates decision-makers and patients about how the field can make health systems more effective and efficient by targeting better treatments to only those who will benefit.

- **Advocacy:** To help facilitate the development of personalized medicine tests and therapies, PMC engages policymakers to advocate for continued investments in biomedical research as well as modernized regulatory, coverage and payment policies that support access to personalized medicine.

- **Evidence Development:** To encourage the swifter adoption of personalized medicine by payers and health care providers, PMC helps build the evidence base necessary to demonstrate the clinical and economic value of personalized medicine.

“Personalized medicine is transforming the practice of medicine, and PMC is playing a critical role in bringing together all of the stakeholders to help make that happen.”

— Raju Kucherlapati, Ph.D., Paul C. Cabot Professor of Genetics, Harvard Medical School
PMC members are leading the movement toward personalized medicine to benefit patients and health systems around the world.

**Member Committees/Working Groups**

- **Public Policy Committee**
  - Patient Advocacy Organization Working Group
  - Pharmaceutical and Diagnostics Working Group

- **Science Policy Committee**
  - Health Care Working Group
  - Value Assessment Working Group

- **Ad Hoc Working Group**
  - Health Data Working Group
  - Pharmacogenomics Working Group

**Member Benefits**

- **Contact**
  2,000+ leaders in personalized medicine via PMC’s member database

- **Interact with**
  200+ thought leaders from Congress, FDA, CMS and the private sector at member meetings and events

- **Save 40%** on registration for the Annual Personalized Medicine Conference

- **Attend Member Meetings and Events** at no charge

- **Discounted Subscription Offers** for outlets including GenomeWeb, STAT, and The Journal of Precision Medicine

- **Receive Copies** of PMC publications and reports
PMC MEMBERSHIP

PMC is an international, multi-stakeholder 501(c)3 nonprofit organization with members that are committed to science-driven, evidence-based health care.

CLINICAL LABORATORY TESTING SERVICES
Dasman Diabetes Institute
Dynamic DNA Laboratories
Invitae
Laboratory Corporation of America (LabCorp)
Quest Diagnostics

DIAGNOSTIC COMPANIES
10x Genomics
Agenda NV
Agilent Technologies
Alacris Theranostics GmbH
Almac Diagnostics
Biocept
Caprion Proteomics
Caris Life Sciences
Circulogene
Cofactor Genomics
Delfi Diagnostics
Exact Sciences
Foundation Medicine, Inc.
GeneCentric Therapeutics
Genomind
GRAIL, Inc.
Guardant Health
Illumina
Myriad Genetics
NanoString Technologies
NeoGenomics Laboratories
NuProbe, Inc.
Olaris Therapeutics
Oncoyte
Personalis
QIAGEN, Inc.
Roche Diagnostics
RxGenomix
Scipher Medicine
Siemens Healthcare Diagnostics, Inc.
SimBioSys, Inc.
SomaLogic, Inc.
Thermo Fisher Scientific

EMERGING BIOTECH/PHARMACEUTICAL COMPANIES
Adaptive Biotechnologies
Alexion Pharmaceuticals
Elevation Oncology, Inc.
EQRx
Freenome
Helix
Legend Biotech
MacroGenics
PAREXEL
Tango Therapeutics

HEALTH INSURANCE COMPANIES
Point32Health

INDUSTRY/TRADE ASSOCIATIONS
American Clinical Laboratory Association
BIO (Biotechnology Innovation Organization)
Biocom California
PhRMA

IT/INFORMATICS COMPANIES
2bPrecise
Assurance Health Data
Change Healthcare
Concert Genetics
DNAmerx
Flatiron Health
GE Healthcare
GNS Healthcare
M2Gen
P4-ML
Paige.ai
PathAI
Syapse
Translational Software
Venebio
Verily Life Sciences
XIFIN, Inc.

LARGE BIOTECH/PHARMACEUTICAL COMPANIES
AbbVie
Amgen, Inc.
AstraZeneca Pharmaceuticals
Bausch Health Companies
Bayer
Biogen
bluebird bio
Blueprint Medicines
Bristol-Myers Squibb
Eli Lilly and Company
Genentech, Inc.
Gilead
GlaxoSmithKline
Johnson & Johnson
Merck & Co.
Novartis
Pfizer, Inc.
Takeda Pharmaceuticals, Inc.

PATIENT ADVOCACY GROUPS
Accelerated Cure Project for Multiple Sclerosis
AiArthritis
Alliance for Aging Research
Alport Syndrome Foundation
Alzheimer’s Foundation of America
American Association of Kidney Patients (AAKP)
Blue Hat Foundation
Bulgarian Association for Personalized Medicine
Cancer101
Cancer Commons
Colorectal Cancer Alliance
CureDuchenne
Emily’s Entourage
EveryLife Foundation
For Rare Diseases
Fight Colorectal Cancer
Friends of Cancer Research
Global Liver Institute
GO2 Foundation for Lung Cancer
HealthyWomen
International Cancer Advocacy Network
KRAS Kickers
LUNGevity Foundation
Multiple Myeloma Research Foundation
National Alliance Against Disparities in Patient Health
National Alliance for Hispanic Health
National Health Council
Rabble Health
Swellter
SynGAP Research Fund
Team Trevor
The Assistance Fund

PERSONALIZED MEDICINE SERVICE PROVIDERS
CareDx
Coriell Life Sciences
Genome Medical
InformedDNA
Michael J. Bauer, M.D., & Associates, Inc.
Sema4
Sengenics
Tempus

RESEARCH, EDUCATION & CLINICAL CARE INSTITUTIONS
Abu Dhabi Health Services Company (SEHA)
Advent Health
American Association for Cancer Research (AACR)
American Medical Association (AMA)
Arizona State University
American Society of Health System Pharmacists (ASHP)
Association for Molecular Pathology (AMP)
Audubon Bioscience
Business Finland
Cancer Treatment Centers of America
Cello Health
BioConsulting
College of American Pathologists
Colorado Center for Personalized Medicine
CommonSpirit Health
Coriell Institute for Medical Research
Duke Center for Research on Personalized Health Care
Essentia Institute of Rural Health
European Infrastructure for Translational Medicine (EATRIS)
Hamad Medical Corporation
Harvard Business School
Hospital Albert Einstein
HudsonAlpha Institute for Biotechnology
iCAN – Digital Precision Cancer Medicine at University of Helsinki
Instituto de Salud Carlos III
Intermountain Healthcare
Johns Hopkins
Individualized Health
Kaiser Permanente
King Faisal Specialist Hospital and Research Centre
MaineHealth
Accountable Care Organization
Manchester University School of Pharmacy
Marshfield Clinic
Mayo Clinic
MD Anderson – Institute for Personalized Cancer Therapy
MITRE Corporation
Moffitt Cancer Center
Morehouse School of Medicine
National Pharmaceutical Council
Nicklaus Children's Hospital Research Institute
NorthShore University HealthSystem
North Carolina Biotechnology Center
Ochsner Health System
Qatar Biobank
Sanford Imagenetics, Sanford Health
Teachers' Retirement System of Kentucky
The Christ Hospital
The Jackson Laboratory
Thomas Jefferson University
Translational Genomics Research Institute (Tgen)
UC Davis Mouse Biology Program
University of Alabama, Birmingham
University of California, San Francisco (UCSF)
University of Pennsylvania Health System
University of Rochester
University of South Florida Morsani College of Medicine
Vanderbilt University Medical Center

RESEARCH TOOL COMPANIES
Octave Biosciences

STRATEGIC PARTNERS
Accenture
Arnold & Porter
Artisan Healthcare Consulting
Bioscience Valuation
BSV GmbH
Boston Healthcare Associates
Bradford Power
Bruce Quinn Associates
Cambridge Cancer Genomics
Cambridge Healthtech Institute
ConText
ConvergeHEALTH by Deloitte
Defined Health
EdgeTech Law, LLP
Fishawack Health
Foley & Lardner, LLP

As of January 2022
## DUES STRUCTURE

*As of January 2022*

<table>
<thead>
<tr>
<th>Category</th>
<th>Dues</th>
</tr>
</thead>
<tbody>
<tr>
<td>Large Public Corporation</td>
<td>$32,000</td>
</tr>
<tr>
<td>Small Public Corporation</td>
<td>$16,000</td>
</tr>
<tr>
<td>Trade Association (based on revenues)</td>
<td></td>
</tr>
<tr>
<td>Private Corporation &gt; 15 FTEs</td>
<td>$6,000</td>
</tr>
<tr>
<td>Professional Society (based on revenues)</td>
<td></td>
</tr>
<tr>
<td>Private Corporation &lt; 15 FTEs</td>
<td>$3,000</td>
</tr>
<tr>
<td>Strategic Partner &gt; 5 FTEs</td>
<td>$3,200</td>
</tr>
<tr>
<td>Strategic Partner &lt; 5 FTEs</td>
<td>$1,500</td>
</tr>
<tr>
<td>Research, Education &amp; Clinical Care Institutions</td>
<td>$3,000</td>
</tr>
<tr>
<td>Patient Advocacy Group</td>
<td>$500</td>
</tr>
</tbody>
</table>

Visit [pmc.portal.membersuite.com](http://pmc.portal.membersuite.com) to join the Coalition.

For more information, contact Kayla Smith, Vice President, Membership & Development, at ksmith@personalizedmedicinecoalition.org.
STAFF

Edward Abrahams, Ph.D.
President

Faswilla Sampson, M.S.
Chief Operating Officer

Cynthia A. Bens
Senior Vice President,
Public Policy

Daryl Pritchard, Ph.D.
Senior Vice President,
Science Policy

Christopher J. Wells, M.P.A.
Senior Vice President, Public Affairs

Kayla Smith
Vice President, Membership & Development

David L. Davenport
Manager, Public Policy

Lindsay Stephens
Program Manager & Secretary to the Board

BOARD OF DIRECTORS

Jay G. Wohlgemuth, M.D.
Board Chair
Quest Diagnostics

William S. Dalton, Ph.D., M.D.
Board Vice Chair
M2Gen

Mark P. Stevenson, M.B.A.
Board Treasurer

Michael Sherman, M.D.
Board Secretary
Point32Health

Bonnie J. Addario
GO: Foundation for Lung Cancer

Antonio L. Andreu, M.D., Ph.D.
European Infrastructure for Translational Medicine (EATRIS)

Randy Burkholder
PhRMA

Kevin Conroy
Exact Sciences

Stephen L. Eck, M.D., Ph.D.
MacroGenics

Lori Frank, Ph.D.
Alzheimer’s Foundation of America

Brad Gray
NanoString Technologies

Kris Joshi, Ph.D.
Change Healthcare

Richard Knight
American Association of Kidney Patients

Peter Maag, Ph.D.
CareDx

Anne-Marie Martin, Ph.D.
GlaxoSmithKline

J. Brian Munroe
Bausch Health Companies

Lincoln Nadauld, M.D., Ph.D.
Intermountain Healthcare

Elizabeth O’Day, Ph.D.
Olaris, Inc.

Michael Pellini, M.D.
Section 32

Kimberly J. Popovits
10x Genomics

Lauren Silvis
Tempus

Apostolia M. Tsimeridou, M.D., Ph.D.
MD Anderson Cancer Center

Michael Vasconcelles, M.D.
Flatiron Health

Werner Verbiest
Janssen Pharmaceutical Companies of Johnson & Johnson